Neurological Biomarkers Market Analysis and Forecast to 2032: By Type (Genomic, Proteomic, Metabolomic, Imaging, Others), Application (Alzheimer Disease, Parkinson Disease, Multiple Sclerosis, Autism Spectrum Disorder, Others), End Use (Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations and Others), and Region
The global Neurological Biomarkers Market was valued at USD 6.8 Billion in 2022 and it is anticipated to grow up to USD 28.6 Billion by 2032, at a CAGR of 15.4% during the forecast period.
Neurological Biomarkers is used to protect against the intentional interference of electronic signals. This equipment can be used to protect against radio frequency interference (RFI), electromagnetic interference (EMI), or other types of signal interference. There are a variety of anti-jamming technologies that can be used, depending on the type of interference that is being protected against. For example, RFI jamming can be countered with frequency-hopping spread spectrum (FHSS) technology, while EMI jamming can be countered with pulse-code modulation (PCM) or other digital modulation techniques.
Global Neurological Biomarkers Market Scope and Report Structure
| Report Attribute | Details |
|---|---|
| Market Size in 2022 | $6.8 bn |
| Market Size in 2032 | $28.6 bn |
| Growth Rate (2022-32) | 15.4% |
| Historic Period | 2016-2021 |
| Forecast Period | 2023-2032 |
| Base Year | 2022 |
| Segments Covered | Type, Application, End-user, and Region |
| Key Companies | Abbott; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; BANYAN BIOMARKERS, INC.; Myriad Genetics, Inc.; DiaGenic ASA; and Quanterix. |
| Regional Scope | North America, Europe, Asia Pacific, Central & South America, Middle East & Africa |
| Analysis Coverage | Market Forecast, Competitive Landscape, Drivers, Trends, Restraints, Opportunities, Value-Chain, PESTLE, Key Events and Developments |
Market Trends and Drivers
Recent advancements in biomarkers, such as biomarker signatures are making neurological diseases more treatable. This has resulted in noninvasive testing, faster drug development, and early diagnosis. Furthermore, digital biomarkers provide various pharmaceutical companies with contextual and supplemental information to conclude clinical trial decisions. National Institute of Neurological Disorders and Stroke provides funding, such as development grants & cooperative agreements, for researchers conducting studies related to biomarker discovery, analytical validation, & clinical validation.
Market Restraints and Challenges
The high cost of Neurological Biomarkers systems is likely to impede the market growth over the forecast period. However, the increment is not significant in the women population. Thus, such increase in Parkinsons disease in men aged 70 years and over is projected to supplement the market growth owing to the increase in demand for biomarkers for diagnosis.
Global Neurological Biomarkers Market Segmental Overview
The report analyses the global Neurological Biomarkers Market based on type, application, end-user, and region.
Global Neurological Biomarkers Market by Type
On the basis of type, it is segmented into genomic, proteomic, metabolomic, imaging, and others. The proteomic segment accounted for the highest revenue share of over xx% in 2022. Genomic biomarkers accounted for the second-largest market share in 2022. Genomic biomarkers present promising opportunities for the development of personalized medicines and diagnostics based on an individual’s specific genetic variations & predisposition to the disease. The methods used for detecting the presence or studying genomic biomarkers for the identification of disease-associated DNA sequence variants include array Comparative Genomic Hybridization (CGH), gene expression profiling, whole-genome association studies using Single Nucleotide Polymorphisms (SNPs), and whole-genome resequencing.
The others segment is anticipated to witness significant CAGR over the forecast period due to the increasing adoption of digital biomarkers in clinical trials patient selection for neurological drugs. For instance, IXICO plc – a digital technology-based company, with expertise in neurosciences-is collaborating with biopharmaceutical companies to validate clinically digital biomarkers and use them in clinical trials. s.
Global Neurological Biomarkers Market by Application
By application, the industry is classified into alzheimer disease, parkinson disease, multiple sclerosis, autism spectrum disorder, and others. The Alzheimer disease application segment accounted for the largest market share of over xx% in 2022 and is expected to remain dominant during the forecast period. This growth is credited to the high disease burden and availability of products for clinical use, such as imaging biomarkers-amyloid PET tracers for diagnosis. Furthermore, the government and non-profit organizations are providing a plethora of research opportunities that may fuel market growth. The Alzheimer Association in collaboration with The Michael J. Fox Foundation for Parkinson Research (MJFF), Alzheimer Research U.K., and the Weston Brain Institute, introduced Biomarkers Across Neurodegenerative Diseases (BAND) that provide research funding for biomarker discovery.
The Parkinson disease application segment is expected to grow at a CAGR of xx% during the forecast period owing to the growing prevalence of the disease and an increasing number of clinical trials for the disease drugs. According to the Parkinson Foundation, around 60,000 people are diagnosed with Parkinson’s disease each year in the U.S. and over 930,000 people were suffering from the disease in 2020. Several ground-breaking research trials are being conducted for improved diagnostics of Parkinson disease. Earlier, protein biomarkers, amino acids, and dopamine metabolites were the prime analytical tools for diagnosing the disease. However, several novel candidates are under investigation for potential diagnostic biomarker.
Global Neurological Biomarkers Market by End-user
By end-use, neurological biomarkers market has been segmented into hospital & hospital laboratories, independent clinical diagnostic centers, research organizations and others. The hospital & hospital laboratories segment accounted for the largest market share of over xx% in 2022. The segment is expected to remain dominant even during the forecast period due to a rise in hospitalization. Furthermore, the ongoing development of healthcare infrastructure is anticipated to enhance the existing hospital facilities. Most of the blood-based biomarker assays are purchased by hospitals and are used in significant volumes. The research organizations & others segment is expected to grow at the fastest CAGR xx% over the forecast years owing to the increased adoption of biomarkers by pharmaceutical companies and Ambulatory Surgery Centers (ASCs) for drug discovery & development.
Geographical Analysis of Global Neurological Biomarkers Market
Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America accounted for the highest market share of over xx% in 2022 and is expected to witness a significant growth rate over the forecast period. The significantly high disease burden, acceptance of biomarkers for diagnostic, drug development & prognostic purposes, and increase in research funding are some key factors contributing to the dominance of the region. Moreover, the increasing product launches along with the rise in demand for biomarkers are expected to have a positive impact on the regional market. Asia Pacific is expected to grow at the fastest CAGR of xx% from 2022 to 2032. An increasing number of clinical trials being conducted in developing countries, such as India and China, rising disease burden, and growing need for targeted drugs in the central nervous system are factors expected to drive the regional market growth.
Major Players in the Global Catamaran Market
The key players in the Neurological Biomarkers Market are Abbott; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; BANYAN BIOMARKERS, INC.; Myriad Genetics, Inc.; DiaGenic ASA; and Quanterixamong others.
COVID-19 Impact
The COVID-19 outbreak has had a significant impact on the market. As employment closures have curtailed import and export activities and closures of diagnostics centers and hospitals. For instance, according to an article titled “Impact of the COVID-19 pandemic on the surveillance, prevention, and control of antimicrobial resistance: a global survey” published in September 2021, there was a reduction in the availability of the nursing, medical, and public health staff for antimicrobial resistance by 71%, 69%, and 64%, respectively. However, with the release COVID-19 restrictions and resumed diagnosis and testing services in industries the studied market is expected to grow over the forecast period. Certain factors propelling the market growth are the rising burden of infectious diseases, technological advancements in microbial identification, increasing food safety concerns, and government initiatives and funding for promoting microbial identification.
Recent Developments
- In May 2020, PerkinElmer launched of new products based on the HTRF technology. The product application includes biomarkers assays, biochemical cytokine-receptor binding assays, and other applications.
- In March 2020, Thermo Fisher Scientific initiated the procedure for the acquisition of QIAGEN N.V. as a part of the business strategy. This transaction values QIAGEN at about US$ 11.5 billion as per the current exchange rates. It includes the consideration of about US$ 1.4 billion of net debt.
- In December 2019, Quest Diagnostics Incorporated acquired specific assets of Boston Clinical Laboratories related to clinical laboratory services business. Boston Clinical Laboratories is a Waltham-based regional provider of laboratory services.
- In July 2019, Quest Diagnostics Incorporated entered into a partnership with Catholic Health Services (CHS). CHS is an integrated health care delivery system that accounts for about a 24% market share on Long Island. Through this partnership, the company will be able to provide laboratory and supply chain expertise, other testing-related services.
- In April 2019, PerkinElmer Inc. acquired Cisbio Bioassays. Cisbio Bioassays has developed its proprietary HTRF technology, a TR-FRET assay platform that has application in Life Sciences. The extension of Cisbio has enabled life science researchers to have access to assay tools for various target types and biological configurations, small molecule, and biologic drug discovery procedures..
Frequently Asked Questions
Q1. How big is the Neurological Biomarkers Market?
Ans. The global Neurological Biomarkers Market was valued at USD 6.8 Billion in 2022 and it is anticipated to grow up to USD 28.6 Billion by 2032, at a CAGR of 15.4% during the forecast period.
Q2. What is the Neurological Biomarkers Market growth rate?
Ans. The growth rate of the Neurological Biomarkers Market is 15.4%
Q3. Which region holds a major market share for the market?
Ans. North America holds a major market share of the Neurological Biomarkers Market in 2021.
Q4. Which segment accounted for the largest Neurological Biomarkers Market share?
Ans. By application, the pharmaceuticals segment accounted for the largest Neurological Biomarkers Market share.
Q5. Who are the key players in the Neurological Biomarkers Market?
Ans. The global Neurological Biomarkers Market report includes players such as Abbott; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; BANYAN BIOMARKERS, INC.; Myriad Genetics, Inc.; DiaGenic ASA; and Quanterix, among others.
Q6. What are the factors driving the Neurological Biomarkers Market growth?
Ans. The major factors driving the growth of the market are the rise in the prevalence of neurological diseases, such as migraines, dementia, Alzheimer disease, brain tumors, and epilepsy.
Q7. What are the key growth strategies of Neurological Biomarkers Market players?
Ans. The key growth strategies of Neurological Biomarkers Market players are product launch and product approval.
Q8. Which region will provide more business opportunities for the Neurological Biomarkers Market during the forecast period?
Ans. The Asia-Pacific region will provide more business opportunities for the Neurological Biomarkers Market during the forecast period.
Table of Contents
Chapter 1. Neurological Biomarkers Market Overview
1.1. Objectives of the Study
1.2. Market Definition and Research & Scope
1.3. Research Limitations
1.4. Research Developments
1.4.1. Secondary Research
1.4.2. Market Size Estimation Technique
1.4.3. Forecasting
1.4.4. Primary Research and Data Validation
Chapter 2. Executive Summary
2.1. Summary
2.2. Key Highlights of the Market
Chapter 3. Premium Insights on the Market
3.1. Market Attractiveness Analysis, by Region
3.2. Market Attractiveness Analysis, By Type
3.3. Market Attractiveness Analysis, By Application
3.4. Market Attractiveness Analysis, By End-use
Chapter 4. Neurological Biomarkers Market Outlook
4.1. Neurological Biomarkers Market Segmentation
4.2. Market Dynamics
4.2.1. Market Drivers
4.2.1.1. Driver 1
4.2.1.2. Driver 2
4.2.1.3. Driver 3
4.2.2. Market Restraints
4.2.2.1. Restraint 1
4.2.2.2. Restraint 2
4.2.3. Market Opportunities
4.2.3.1. Opportunity 1
4.2.3.2. Opportunity 2
4.3. Porter’s Five Forces Analysis
4.3.1. Threat of New Entrants
4.3.2. Threat of Substitutes
4.3.3. Bargaining Power of Buyers
4.3.4. Bargaining Power of Supplier
4.3.5. Competitive Rivalry
4.4. PESTLE Analysis
4.5. Value Chain Analysis
4.5.1. Raw Industry Vertical Suppliers
4.5.2. Manufacturers
4.5.3. Wholesalers and/or Retailers
4.6. Impact of COVID-19 on the Neurological Biomarkers Market
4.7. Impact of the Russia and Ukraine War on the Neurological Biomarkers Market
Chapter 5. Neurological Biomarkers Market By Type
5.1. Market Overview
5.2. Genomic
5.2.1. Key Market Trends & Opportunity Analysis
5.2.2. Market Size and Forecast, by Region, 2022-2032 ($Million)
5.3. Proteomic
5.3.1. Key Market Trends & Opportunity Analysis
5.3.2. Market Size and Forecast, by Region, 2022-2032 ($Million)
5.4. Metabolomic
5.4.1. Key Market Trends & Opportunity Analysis
5.4.2. Market Size and Forecast, by Region, 2022-2032 ($Million)
5.5. Imaging
5.5.1. Key Market Trends & Opportunity Analysis
5.5.2. Market Size and Forecast, by Region, 2022-2032 ($Million)
5.6. Others
5.6.1. Key Market Trends & Opportunity Analysis
5.6.2. Market Size and Forecast, by Region, 2022-2032 ($Million)
Chapter 6. Neurological Biomarkers Market By Application
6.1. Market Overview
6.2. Alzheimer’s Disease
6.2.1. Market Trends & Opportunity Analysis
6.2.2. Market Size and Forecast, by Region, 2022-2032 ($Million)
6.3. Parkinson’s Disease
6.3.1. Market Trends & Opportunity Analysis
6.3.2. Market Size and Forecast, by Region, 2022-2032 ($Million)
6.4. Multiple Sclerosis
6.4.1. Market Trends & Opportunity Analysis
6.4.2. Market Size and Forecast, by Region, 2022-2032 ($Million)
6.5. Autism Spectrum Disorder
6.5.1. Market Trends & Opportunity Analysis
6.5.2. Market Size and Forecast, by Region, 2022-2032 ($Million)
6.6. Others
6.6.1. Market Trends & Opportunity Analysis
6.6.2. Market Size and Forecast, by Region, 2022-2032 ($Million)
Chapter 7. Neurological Biomarkers Market By End-use
7.1. Market Overview
7.2. Hospital & Hospital Laboratories
7.2.1. Key Market Trends & Opportunity Analysis
7.2.2. Market Size and Forecast, by Region, 2022-2032 ($Million)
7.3. Independent Clinical Diagnostic Centers
7.3.1. Key Market Trends & Opportunity Analysis
7.3.2. Market Size and Forecast, by Region, 2022-2032 ($Million)
7.4. Research Organizations and Others
7.4.1. Key Market Trends & Opportunity Analysis
7.4.2. Market Size and Forecast, by Region, 2022-2032 ($Million)
Chapter 8. Flexible Endoscope Market, by Region
8.1. Overview
8.2. North America
8.2.1. Key Market Trends & Opportunity Analysis
8.2.2. North America Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.2.3. North America Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.2.4. North America Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.2.5. North America Neurological Biomarkers Market Size and Forecast by Country, 2022-2032 , ($Million)
8.2.6. The U.S.
8.2.6.1. The U.S. Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.2.6.2. The U.S. Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.2.6.3. The U.S. Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.2.7. Canada
8.2.7.1. Canada Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.2.7.2. Canada Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.2.7.3. Canada Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.2.8. Mexico
8.2.8.1. Mexico Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.2.8.2. Mexico Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.2.8.3. Mexico Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.3. Europe
8.3.1. Key Market Trends & Opportunity Analysis
8.3.2. Europe Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.3.3. Europe Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.3.4. Europe Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.3.5. Europe Neurological Biomarkers Market Size and Forecast by Country, 2022-2032 , ($Million)
8.3.6. Germany
8.3.6.1. Germany Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.3.6.2. Germany Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.3.6.3. Germany Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.3.7. France
8.3.7.1. France Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.3.7.2. France Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.3.7.3. France Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.3.8. U.K.
8.3.8.1. U.K. Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.3.8.2. U.K. Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.3.8.3. U.K. Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.3.9. Spain
8.3.9.1. Spain Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.3.9.2. Spain Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.3.9.3. Spain Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.3.10. Italy
8.3.10.1. Italy Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.3.10.2. Italy Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.3.10.3. Italy Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.3.11. Rest of Europe
8.3.11.1. Rest of Europe Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.3.11.2. Rest of Europe Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.3.11.3. Rest of Europe Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.4. Asia-Pacific
8.4.1. Key Market Trends & Opportunity Analysis
8.4.2. Asia-Pacific Neurological Biomarkers Market Size and Forecast by Country, 2022-2032 , ($Million)
8.4.3. Asia-Pacific Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.4.4. Asia-Pacific Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.4.5. Asia-Pacific Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.4.6. China
8.4.6.1. China Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.4.6.2. China Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.4.6.3. China Neurological Biomarkers Market Size and Forecast By Type Industry Vertical, 2022-2032 , ($Million)
8.4.7. India
8.4.7.1. India Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.4.7.2. India Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.4.7.3. India Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.4.8. Japan
8.4.8.1. Japan Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.4.8.2. Japan Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.4.8.3. Japan Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.4.9. South Korea
8.4.9.1. South Korea Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.4.9.2. South Korea Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.4.9.3. South Korea Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.4.10. Rest of APAC
8.4.10.1. Rest of APAC Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.4.10.2. Rest of APAC Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.4.10.3. Rest of APAC Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.5. Rest of the World
8.5.1. Key Market Trends & Opportunity Analysis
8.5.2. Rest of the World Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.5.3. Rest of the World Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.5.4. Rest of the World Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.5.5. Rest of the World Neurological Biomarkers Market Size and Forecast by Country, 2022-2032 , ($Million)
8.5.6. Latin America
8.5.6.1. Latin America Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.5.6.2. Latin America Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.5.6.3. Latin America Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.5.7. Middle East
8.5.7.1. Middle East Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.5.7.2. Middle East Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.5.7.3. Middle East Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
8.5.8. Africa
8.5.8.1. Africa Neurological Biomarkers Market Size and Forecast By Type, 2022-2032 , ($Million)
8.5.8.2. Africa Neurological Biomarkers Market Size and Forecast By Application, 2022-2032 , ($Million)
8.5.8.3. Africa Neurological Biomarkers Market Size and Forecast By End-use, 2022-2032 , ($Million)
Chapter 9. Competitive Landscape
9.1. Market Overview
9.2. Market Share Analysis/Key Player Positioning
9.3. Vendor Benchmarking
9.4. Developmental Strategy Benchmarking
9.4.1. New Product Development
9.4.2. Product Launches
9.4.3. Business Expansions
9.4.4. Partnerships, Joint Ventures, and Collaborations
9.4.5. Mergers and Acquisitions
Chapter 10. Company Profiles
10.1. Abbott Laboratories
10.1.1. Company Snapshot
10.1.2. Financial Performance
10.1.3. Product Offerings
10.1.4. Key Strategic Initiatives
10.1.5. SWOT Analysis
10.2. Thermo Fisher Scientific, Inc.
10.2.1. Company Snapshot
10.2.2. Financial Performance
10.2.3. Product Offerings
10.2.4. Key Strategic Initiatives
10.2.5. SWOT Analysis
10.3. Bio-Rad Laboratories, Inc.
10.3.1. Company Snapshot
10.3.2. Financial Performance
10.3.3. Product Offerings
10.3.4. Key Strategic Initiatives
10.3.5. SWOT Analysis
10.4. Merck & Co., Inc.
10.4.1. Company Snapshot
10.4.2. Financial Performance
10.4.3. Product Offerings
10.4.4. Key Strategic Initiatives
10.4.5. SWOT Analysis
10.5. Johnson & Johnson Services, Inc.
10.5.1. Company Snapshot
10.5.2. Financial Performance
10.5.3. Product Offerings
10.5.4. Key Strategic Initiatives
10.5.5. SWOT Analysis
10.6. Banyan Biomarkers, Inc.
10.6.1. Company Snapshot
10.6.2. Financial Performance
10.6.3. Product Offerings
10.6.4. Key Strategic Initiatives
10.6.5. SWOT Analysis
10.7. Myriad Genetics, Inc.
10.7.1. Company Snapshot
10.7.2. Financial Performance
10.7.3. Product Offerings
10.7.4. Key Strategic Initiatives
10.7.5. SWOT Analysis
10.8. DiaGenic ASA
10.8.1. Company Snapshot
10.8.2. Financial Performance
10.8.3. Product Offerings
10.8.4. Key Strategic Initiatives
10.8.5. SWOT Analysis
10.9. Quanterix
10.9.1. Company Snapshot
10.9.2. Financial Performance
10.9.3. Product Offerings
10.9.4. Key Strategic Initiatives
10.9.5. SWOT Analysis
*The list of company is subject to change during the final compilation of the report
Key Players
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Banyan Biomarkers, Inc.
- Myriad Genetics, Inc.
- DiaGenic ASA
- Quanterix
Global Neurological Biomarkers Market Segmentation
By Type
- Genomic
- Proteomic
- Metabolomic
- Imaging
- Others
By Application
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Autism Spectrum Disorder
- Others
By End-user
- Hospital & Hospital Laboratories
- Independent Clinical Diagnostic Centers
- Research Organizations
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Rest of World
- Latin America
- Middle East
- Africa